Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion nabs $239M and an up to $1B part­ner­ship with Bay­er as AI race heats up

Some biotechs strug­gle for cash. Re­cur­sion, late­ly, seems to be swim­ming in it.

To­day, hav­ing al­ready raised over $180 mil­lion in the last two years, the Salt Lake City-based AI drug de­vel­op­er an­nounced a $239 mil­lion Se­ries D. That’s more than any US or Eu­ro­pean biotech has raised in a round this year and more than all but two biotechs raised last year. (Mab­well, a Shang­hai-based an­ti­body de­vel­op­er, raised $278 mil­lion in a Se­ries A in April.)

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.